Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the USA on 26th November 2019. The patent number is 10,488,530.
Related Posts
Dr. Shakar Jafari wins prestigious 'Women in Innovation' award for groundbreaking contributions to healthcare.
Graduate secures vital government backing for innovative cancer treatment, targeting global markets with Sirius Programme.
TRUEinvivo joined SyndicateRoom investment platform in February 2019, leveraging its network to connect with potential investors, alongside Nexus Investment Ventures Ltd,
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
